Article Versions Notes

Grab AL, Kim PS, John L, Bisht K, Wang H, Baumann A, Van de Velde H, Sarkar I, Shome D, Reichert P, et al. Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma. Cells. 2024; 13(10):879. https://doi.org/10.3390/cells13100879

Grab, Anna Luise, Peter S. Kim, Lukas John, Kamlesh Bisht, Hongfang Wang, Anja Baumann, Helgi Van de Velde, Irene Sarkar, Debarati Shome, Philipp Reichert, and et al. 2024. "Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma" Cells 13, no. 10: 879. https://doi.org/10.3390/cells13100879

Grab, A. L., Kim, P. S., John, L., Bisht, K., Wang, H., Baumann, A., Van de Velde, H., Sarkar, I., Shome, D., Reichert, P., Manta, C., Gryzik, S., Reijmers, R. M., Weinhold, N., & Raab, M. S. (2024). Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma. Cells, 13(10), 879. https://doi.org/10.3390/cells13100879